Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 8
2002 6
2003 7
2004 16
2005 28
2006 59
2007 77
2008 93
2009 135
2010 134
2011 133
2012 156
2013 180
2014 170
2015 138
2016 111
2017 111
2018 82
2019 73
2020 54
2021 56
2022 59
2023 47
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

1,704 results

Results by year

Filters applied: . Clear all
Page 1
Temsirolimus.
Schulze M, Stock C, Zaccagnini M, Teber D, Rassweiler JJ. Schulze M, et al. Recent Results Cancer Res. 2014;201:393-403. doi: 10.1007/978-3-642-54490-3_24. Recent Results Cancer Res. 2014. PMID: 24756806 Review.
In this study, median overall survival was 10.9 versus 7.3 months and objective response rates were 8.6% in temsirolimus recipients versus 4.8% IFN-alpha recipient group. Temsirolimus monotherapy recipients experienced significantly fewer grade 3 or 4 adverse events …
In this study, median overall survival was 10.9 versus 7.3 months and objective response rates were 8.6% in temsirolimus recipients v …
Temsirolimus.
Ma WW, Jimeno A. Ma WW, et al. Drugs Today (Barc). 2007 Oct;43(10):659-69. doi: 10.1358/dot.2007.43.10.1148059. Drugs Today (Barc). 2007. PMID: 17987219 Review.
Temsirolimus (CCI-779), a small molecule inhibitor of mTOR protein, is a water-soluble synthetic rapamycin ester that has been developed in both oral and intravenous (i.v.) formulations. ...Patients receiving temsirolimus alone achieved longer survival than those re …
Temsirolimus (CCI-779), a small molecule inhibitor of mTOR protein, is a water-soluble synthetic rapamycin ester that has been develo …
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. ...Ibrutinib was better tolerated than temsirolimus …
BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown s …
Temsirolimus.
Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ. Stock C, et al. Recent Results Cancer Res. 2010;184:189-97. doi: 10.1007/978-3-642-01222-8_13. Recent Results Cancer Res. 2010. PMID: 20072839 Review.
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors. ...In this study, median overa …
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently block …
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
Of the remaining 35 patients, 18 were randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-dinutuximab. Median follow-up was 1.26 years (IQR 0.68-1.61) among all eligible participants. Of the 18 patients assigned to irinotecan-temozol …
Of the remaining 35 patients, 18 were randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-din …
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. Aghajanian C, et al. Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24. Gynecol Oncol. 2018. PMID: 29804638 Free PMC article. Clinical Trial.
METHODS: In this randomized phase II trial, patients with chemotherapy-naive stage III/IVA (with measurable disease) and stage IVB or recurrent (with or without measurable disease) endometrial cancer were randomly assigned to treatment with PC plus bevacizumab (Arm 1), PC plus …
METHODS: In this randomized phase II trial, patients with chemotherapy-naive stage III/IVA (with measurable disease) and stage IVB or recurr …
Temsirolimus metabolic pathways revisited.
Shokati T, Hartmann M, Davari B, Klawitter J, Klawitter J, Christians U. Shokati T, et al. Xenobiotica. 2020 Jun;50(6):640-653. doi: 10.1080/00498254.2019.1678793. Epub 2019 Oct 23. Xenobiotica. 2020. PMID: 31596164
Temsirolimus, a derivative of sirolimus, exhibits potent antitumor properties. ...Moreover, enzyme kinetic parameters of temsirolimus metabolite formation as well as the contribution of individual recombinant cytochrome P450 (CYP) enzymes to temsirolimus meta …
Temsirolimus, a derivative of sirolimus, exhibits potent antitumor properties. ...Moreover, enzyme kinetic parameters of temsiroli …
Temsirolimus: a safety and efficacy review.
Bukowski RM. Bukowski RM. Expert Opin Drug Saf. 2012 Sep;11(5):861-79. doi: 10.1517/14740338.2012.713344. Epub 2012 Aug 6. Expert Opin Drug Saf. 2012. PMID: 22861825 Review.
Temsirolimus binds to the cytoplasmic protein FKBP-12, and the complex binds and inhibits mTOR. AREAS COVERED: This review summarizes the clinical findings and safety of temsirolimus in RCC patients. EXPERT OPINION: A Phase III clinical trial has demonstrated that …
Temsirolimus binds to the cytoplasmic protein FKBP-12, and the complex binds and inhibits mTOR. AREAS COVERED: This review summarizes …
Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.
Hoy SM, McKeage K. Hoy SM, et al. Drugs. 2010 Oct 1;70(14):1819-29. doi: 10.2165/11204940-000000000-00000. Drugs. 2010. PMID: 20836575 Review.
Therapy with intravenous temsirolimus 175 mg once weekly for 3 weeks followed by 75 mg once weekly (higher temsirolimus dosage), but not 25 mg once weekly (lower temsirolimus dosage), was significantly more effective than single-agent chemotherapy of the inve …
Therapy with intravenous temsirolimus 175 mg once weekly for 3 weeks followed by 75 mg once weekly (higher temsirolimus dosage …
Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G, Smith SM, Berkenblit A, Coiffier B. Hess G, et al. Semin Oncol. 2009 Dec;36 Suppl 3:S37-45. doi: 10.1053/j.seminoncol.2009.10.012. Semin Oncol. 2009. PMID: 19963099 Review.
Once-weekly intravenous temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly (175/75) significantly improved progression-free survival (hazard ratio = 0.44; P = .0009) versus investigator's choice therapy. ...The results of this trial established a recommended cli …
Once-weekly intravenous temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly (175/75) significantly improved progression-fre …
1,704 results